AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Vaccine Partnering Terms and Agreements Deal Trends, Players and Financials Directory 2014-2019 - ResearchAndMarkets.com

May 17, 2019

DUBLIN--(BUSINESS WIRE)--May 17, 2019--

The “Global Vaccine Partnering Terms and Agreements 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Vaccine Partnering Terms and Agreements 2014-2019: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 450 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 450 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field.

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it.

Global Vaccine Partnering Terms and Agreements 2014-2019: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Global Vaccine Partnering Terms and Agreements 2014-2019: Deal trends, players and financials includes:

  • Trends in vaccine dealmaking in the biopharma industry since 2014
  • Analysis of vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life vaccine deals
  • Access to over 450 vaccine deal documents
  • The leading vaccine deals by value since 2014
  • Most active vaccine dealmakers since 2014
  • The leading vaccine partnering resources

In Global Vaccine Partnering Terms and Agreements 2014-2019: Deal trends, players and financials, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target
  • Specific technology type

Key Topics Covered:

1. Introduction

2. Trends in Vaccines dealmaking

2.1. Introduction

2.2. Vaccines partnering over the years

2.3. Most active Vaccines dealmakers

2.4. Vaccines partnering by deal type

2.5. Vaccines partnering by therapy area

2.6. Deal terms for Vaccines partnering

2.6.1 Vaccines partnering headline values

2.6.2 Vaccines deal upfront payments

2.6.3 Vaccines deal milestone payments

2.6.4 Vaccines royalty rates

3. Leading Vaccines deals

3.1. Introduction

3.2. Top Vaccines deals by value

4. Most active Vaccines dealmakers

4.1. Introduction

4.2. Most active Vaccines dealmakers

4.3. Most active Vaccines partnering company profiles

5. Vaccines contracts dealmaking directory

5.1. Introduction

5.2. Vaccines contracts dealmaking directory

6. Vaccines dealmaking by technology type

7. Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Vaccines deals by company A-Z

Appendix 2 - Vaccines deals by stage of development

Appendix 3 - Vaccines deals by deal type

Appendix 4 - Vaccines deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/v2k9se

View source version on businesswire.com:https://www.businesswire.com/news/home/20190517005357/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/17/2019 10:56 AM/DISC: 05/17/2019 10:56 AM

http://www.businesswire.com/news/home/20190517005357/en